Alternatively spliced tissue factor synergizes with the estrogen receptor pathway in promoting breast cancer progression


Kocaturk B., Tieken C., Vreeken D., Unlu B., Engels C. C., de Kruijf E. M., ...More

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol.13, no.9, pp.1683-1693, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 13 Issue: 9
  • Publication Date: 2015
  • Doi Number: 10.1111/jth.13049
  • Journal Name: JOURNAL OF THROMBOSIS AND HAEMOSTASIS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1683-1693
  • Keywords: blood coagulation, cell movement, cell proliferation, integrin beta1, tumors, FACTOR EXPRESSION, TUMOR-GROWTH, CELLS, PROLIFERATION, ANGIOGENESIS, ACTIVATION, COAGULATION, TAMOXIFEN, THERAPY, TARGET
  • Hacettepe University Affiliated: Yes

Abstract

BackgroundProcoagulant full-length tissue factor (flTF) and its minimally coagulant alternatively spliced isoform (asTF), promote breast cancer (BrCa) progression via different mechanisms. We previously showed that flTF and asTF are expressed by BrCa cells, resulting in autoregulation in a cancer milieu. BrCa cells often express hormone receptors such as the estrogen receptor (ER), leading to the formation of hormone-regulated cell populations.